Valuation : Modalis Therapeutics Corporation

Market Cap 3.44B 21.53M 18.55M 17.4M 15.88M 29.91M 2.06B 30.01M 206M 80.52M 1.04B 80.84M 79.08M P/E 2024
-3.57x
P/E 2025 -2.01x
Enterprise Value 632M 3.95M 3.41M 3.19M 2.92M 5.49M 378M 5.51M 37.89M 14.78M 191M 14.84M 14.52M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
91.09%
Yield 2024 *
-
Yield 2025 -
08-10 Modalis Therapeutics Corporation Reports Earnings Results for the Half Year Ended June 30, 2026 CI
06-11 Modalis Therapeutics Corporation announced that it has received ¥2.64 million in funding from Evolution Capital Management LLC CI
05-26 Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLC CI
05-13 Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-12 Modalis Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25-08-25 Modalis Therapeutics Corporation announced that it has received ¥3.072 million in funding from Evolution Capital Management LLC CI
25-08-06 Modalis Therapeutics Corporation announced that it expects to receive ¥3.072 million in funding from Evolution Capital Management LLC CI
25-07-06 Modalis Therapeutics Licenses Gene Therapy IP from Broad Institute for Muscular Dystrophy Treatment MT
25-06-15 Modalis Issues Restricted Stock to Subsidiary Employee Under Incentive Plan MT
25-06-09 SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy CI
25-04-30 Modalis Issues 21,900 Shares for Restricted Stock Remuneration MT
25-01-27 Modalis Therapeutics Secures Japanese Patent for Gene Therapy MT
25-01-06 JCR Pharmaceuticals and Modalis Therapeutics Advance Gene Therapy Research for CNS Disease MT
Current month+10.00%
1 month+10.00%
3 months-26.67%
6 months-44.07%
Current year-41.07%
1 week 32
Extreme 32
34
1 month 29
Extreme 29
34
Current year 29
Extreme 29
83
1 year 29
Extreme 29
97
3 years 29
Extreme 29
203
5 years 29
Extreme 29
1,667
10 years 29
Extreme 29
4,070
Manager TitleAgeSince
Chief Executive Officer 57 2015-12-31
Director of Finance/CFO 63 -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 2015-12-31
Director/Board Member 60 2015-12-31
Director/Board Member 67 2015-12-31
Date Insider Type Main position Quantity % Market Cap.
9/24/24 Others

Founder

10,000 0.0220%
9/24/24 Others

Founder

10,000 0.0220%
9/24/24 Others

Founder

6,000 0.0132%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-63.33%-82.45% 21.53M
-1.59%-3.35%+52.37%+93.70% 69.54B
-1.34%-0.75%+48.21%+91.86% 64.97B
+0.30%-0.69%+52.56%+10.23% 26.51B
-2.35%-5.75%-12.90%+448.54% 25.89B
-8.37%-12.43%+2.08%-16.71% 25.64B
-0.96%+10.36%+283.06%+436.50% 20.22B
-0.51%+0.23%+35.77%-18.70% 19.98B
-1.91%-4.37%+13.28%+535.19% 15.69B
-1.47%+0.68%+45.51%+143.08% 13.49B
Average -1.82%-1.73%+45.66%+164.12% 28.19B
Weighted average by Cap. -1.93%-1.50%+53.72%+151.49%

Financials

2024 2025
Net sales - -
Net income -1.32B -8.23M -7.09M -6.65M -6.07M -11.44M -787M -11.47M -78.91M -30.79M -397M -30.91M -30.24M -2.15B -13.45M -11.59M -10.87M -9.92M -18.69M -1.29B -18.75M -129M -50.31M -649M -50.51M -49.41M
Net Debt -3.58B -22.35M -19.26M -18.06M -16.48M -31.05M -2.14B -31.15M -214M -83.58M -1.08B -83.9M -82.08M -2.81B -17.58M -15.15M -14.2M -12.96M -24.42M -1.68B -24.5M -168M -65.74M -848M -66M -64.56M
Logo Modalis Therapeutics Corporation
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
Employees
-
Date Price Change Volume
26-08-28 JP¥33.00 0.00% 966,300
26-08-27 JP¥33.00 0.00% 131,300
26-08-26 JP¥33.00 0.00% 385,000
26-08-25 JP¥33.00 0.00% 706,900
26-08-24 JP¥33.00 0.00% 98,700

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4883 Stock